Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for OTSKY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for OTSKY and 80,000+ other tickers.
See exactly how OTSKY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for OTSKY and 80,000+ other tickers.
Otsuka Holdings Co., Ltd. engages in the management of its group companies which are in the pharmaceuticals business. It operates through the following segments: Pharmaceuticals, Nutraceuticals, Consumer Products, and Others. The Pharmaceuticals segment manufactures therapeutic drugs and infusions focusing on the central nervous system, oncology, and infectious diseases. The Nutraceuticals segment develops and markets nutrition products such as nutritional food, quasi-drugs, health drinks, and dietary supplements for homes, medical facilities, and nursing care units. The Consumer Products…
This expansion of IV solutions manufacturing will help enhance supply-chain resiliency, support portfolio development and advance non-DEHP innovation for the North American IV solutions market. Joint venture announces over $500M IV solutions manufacturing expansion in Austin, TX Expansion aimed at improving IV solutions supply resiliency and quality, and accelerating non-DEHP new product development in North America via fully automated technology First major milestone toward fulfilling the commitments of the joint venture finalized in May 2025 between ICU Medical, Inc. and Otsuka Pharmaceutical Factory America, Inc. AUSTIN, Texas, July 9, 2026 /PRNewswire/ -- Otsuka ICU Medical LLC today announced plans for an over $500 million expansion to its US IV solutions manufacturing through a new facility and significant upgrades to its existing operations in Austin, Texas.
AstraZeneca (OTCMKTS:AZNCF - Get Free Report) and Otsuka (OTCMKTS:OTSKY - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk. Insider and Institutional Ownership 40.9% of AstraZeneca shares are held
Otsuka Holdings Co., Ltd. (OTSKY) M&A Call Prepared Remarks Transcript
Otsuka (OTCMKTS:OTSKY - Get Free Report) and Santen Pharmaceutical (OTCMKTS:SNPHY - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability. Profitability This table compares Otsuka and Santen Pharmaceutical's net
Mayne Pharma Group (OTCMKTS:MAYNF - Get Free Report) and Otsuka (OTCMKTS:OTSKY - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership. Analyst Recommendations This is a summary of recent